Equities

Caribou Biosciences Inc

CRBU:NSQ

Caribou Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.07
  • Today's Change0.00 / 0.00%
  • Shares traded1.22m
  • 1 Year change-60.72%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

  • Revenue in USD (TTM)33.11m
  • Net income in USD-123.44m
  • Incorporated2011
  • Employees158.00
  • Location
    Caribou Biosciences Inc2929 7TH STREET, STE 120BERKELEY 94710United StatesUSA
  • Phone+1 (510) 982-6030
  • Fax+1 (302) 531-3150
  • Websitehttps://www.cariboubio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Context Therapeutics Inc0.00-18.57m169.50m5.00--1.68-----1.06-1.060.001.350.00----0.00-28.46---29.68--------------0.00-------61.53------
Seres Therapeutics Inc374.00k-162.11m172.19m233.00------460.40-1.18-1.180.0027-0.57420.001--0.02861,605.15-44.53-41.51-59.82-54.13-----43,343.58-170.140.889-17.646.65--1,672.2434.9154.54--32.72--
Galectin Therapeutics Inc0.00-48.03m172.51m14.00---------0.7831-0.78310.00-1.320.00----0.00-185.54-92.08-382.33-121.97-----------8.598.29-------15.26------
DiaMedica Therapeutics Inc0.00-19.90m176.55m18.00--3.30-----0.5238-0.52380.001.250.00----0.00-33.49-45.38-34.98-48.24------------0.0006-------41.72---13.65--
Lineage Cell Therapeutics Inc6.19m-24.19m177.51m75.00--2.60--28.69-0.1342-0.13420.03430.36170.0577--18.2582,480.00-22.57-19.53-26.03-22.5990.8389.13-391.25-370.88----0.0017---39.1612.3918.22---27.16--
Shattuck Labs Inc4.12m-85.28m178.50m75.00--1.61--43.28-1.85-1.850.08832.320.029----54,986.67-60.08-29.14-66.66-32.42-----2,067.99-565.33----0.00--154.14-40.6214.37---19.15--
Atossa Therapeutics Inc0.00-25.91m183.61m10.00--2.29-----0.2064-0.20640.000.63740.00----0.00-26.68-29.97-28.00-32.55------------0.00-------11.62---33.90--
Generation Bio Co13.17m-158.43m185.54m174.00--1.61--14.08-2.39-2.390.19891.730.0393--77.4975,712.64-47.28-36.96-51.64-39.21-----1,202.56-8,879.44----0.00----177.317.34--19.61--
Caribou Biosciences Inc33.11m-123.44m187.05m158.00--0.6025--5.65-1.39-1.390.37633.440.0917--15.61209,576.00-34.17---37.56-------372.78-----1,231.110.00--148.91---2.66------
Vaxart Inc13.93m-75.66m189.78m109.00--2.37--13.63-0.4707-0.47070.08610.35180.1178--5.80127,779.80-64.01-49.60-73.18-54.86-----543.21-1,398.00---226.730.0507--6,796.2612.1523.47--21.49--
CytoDyn Inc0.00-51.32m194.26m9.00---------0.0527-0.05270.00-0.11030.00----0.00-444.45-259.15-----------232,918.20---2.76--------35.70------
Sangamo Therapeutics Inc12.28m-249.68m199.93m405.00--8.44--16.29-1.38-1.380.06640.11380.0587--7.4530,313.58-119.44-26.09-153.51-31.04-----2,033.68-136.53----0.00--58.3415.85-34.09---13.25--
MacroGenics Inc41.02m-136.37m205.73m339.00--3.56--5.02-2.19-2.190.65830.92180.16196.626.51120,997.00-53.82-37.76-67.56-45.5379.37---332.47-133.962.69-172.620.00---61.33-0.460692.44---41.13--
Data as of Sep 20 2024. Currency figures normalised to Caribou Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

34.99%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20246.28m6.95%
The Vanguard Group, Inc.as of 30 Jun 20244.48m4.96%
PFM Health Sciences LPas of 30 Jun 20244.08m4.52%
BofA Securities, Inc.as of 30 Jun 20243.57m3.95%
Point72 Asset Management LPas of 30 Jun 20242.88m3.19%
Dimensional Fund Advisors LPas of 30 Jun 20242.44m2.70%
Elmwood Wealth Management, Inc.as of 30 Jun 20242.33m2.58%
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 31 Jul 20242.00m2.21%
Geode Capital Management LLCas of 30 Jun 20241.91m2.11%
Kynam Capital Management LPas of 30 Jun 20241.65m1.82%
More ▼
Data from 30 Jun 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.